Initial Sales Sample Clauses

Initial Sales. In relation to the Initial Sales of the Affordable Housing Units the following provisions shall apply:­ 3 .1.1 The Owner shall give the Council not less than four (4) months' written notice of the date when all the Affordable Housing Units will be ready for Occupation and notify the Council of the proposed Market Value(s) and; i. if the Council does not give notice to dispute the Market Value within 28 days of the notice in 3 . 1.1 the Market Value shall be deemed to be accepted
Sample 1
AutoNDA by SimpleDocs
Initial Sales. For Sales which are confirmed by CMS to be payable as an Initial Sale, Aetna will, if permitted by Applicable Law, advance the full “Initial Rate” set forth in Schedule 1 hereto, in one or more payments, during the calendar year in which the effective date of the policy occurs. The full amount of the “Initial Rate” will be paid for Initial Sales regardless of the month in which the effective date falls (i.e., same amount will be paid if the effective date is January 1st or December 1st). Upline Agreement 2015 30 Below is an example of how the Commission will be paid on an Initial Sale of a Medicare Advantage Plan under these circumstances, using $400 as the Commission rate payable for Initial Sales: Example Using An Initial Rate of $400 Effective Date Number of Months Paid Total Amount Paid 1/1/2014 12 months $ 400.00 2/1/2014 12 months $ 400.00 3/1/2014 12 months $ 400.00 4/1/2014 12 months $ 400.00 5/1/2014 12 months $ 400.00 6/1/2014 12 months $ 400.00 7/1/2014 12 months $ 400.00 8/1/2014 12 months $ 400.00 9/1/2014 12 months $ 400.00 10/1/2014 12 months $ 400.00 11/1/2014 12 months $ 400.00 12/1/2014 12 months $ 400.00 The rates set forth above are merely for example purposes and not a guarantee or representation of any rates set forth in Schedule 1 of this Appendix A.
Sample 1
Initial Sales. The initial sales price for each AH Unit shall be calculated by GCHA in accordance with Section 5 of this Agreement and the formulas and assumptions set forth in Section 8-302.B of the Affordable Housing Requirements. Developer shall work, in cooperation with the GCHA, to complete the initial sale of each of the AH Units to an applicant determined by GCHA to be a qualified buyer in accordance with the Affordable Housing Requirements, and selected by GCHA in accordance with the lottery process set forth in the Affordable Housing Requirements. Developer shall conduct the initial sale of each of the AH Units in accordance with the following: a. Developer shall make available Developer's real estate agent to act as a transaction broker for the sale of the AH Units; b. Developer shall provide GCHA with a marketing packet for the Project at least one-hundred twenty (120) days prior to the estimated completion of each AH Unit. The packet shall include descriptions, spec information, a copy of the CC&Rs, estimated POA dues, and POA organizational documents and any rules and regulations. c. Developer shall hold at least one (1) open house at the AH Unit for sale or a model AH Unit prior to the lottery to be conducted by GCHA in accordance with the Affordable Housing Requirements. Notwithstanding anything to the contrary contained in this Agreement, GCHA may, at any time, subject to the rights of any tenant(s), choose to purchase an AH Unit for the initial sales price established for such AH Unit.
Sample 1
Initial Sales. The Developer agrees to deliver to the Monitoring Agent the income, asset and age certifications, deeds and Affordable Housing Restrictions with respect to initial sales of Affordable Units as required under the Regulatory Agreement (the “Initial Sales Data”). The Monitoring Agent agrees to review the Initial Sales Data and determine the substantive compliance of the Project with the Affordability Requirement in accordance with the rules of the Subsidizing Agency. The Monitoring Agent shall also ensure substantive compliance with the approved Marketing Plan and lottery process. Upon completion of its review of Initial Sales Data, the Monitoring Agent shall deliver to the Subsidizing Agency and the Municipality a copy of such data together with the Monitoring Agent’s determination of whether the Affordability Requirement has been met. The Subsidizing Agency shall make the final determination of whether the Affordability Requirement has been met and shall notify the Municipality of its determination.
Sample 1
Initial Sales. About one full life cycle. Target sales volume is: 5,000,000 to 10,000,000 seeds.
Sample 1
Initial Sales. Initial Sales: Applicable.
Sample 1
Initial Sales. On the Initial Closing Date (as hereinafter defined), COVR agrees to issue and sell to Vault and Vault agrees to pay for and acquire from COVR, 320,000 units (each a "Unit"), each of which shall consist of one share of COVR Common Stock, $0.01 par value (the "COVR Common Stock") and one warrant to purchase one share of COVR Common Stock (each a "Warrant"), at a price of $0.625 per Unit (the "Purchase Price Per Unit"), the closing sale price of the COVR Common Stock on May 30, 2000, for an aggregate purchase price of $200,000. On the Second Closing Date (as hereinafter defined), COVR agrees to issue and sell to Vault and Vault agrees to pay for and acquire from COVR, 320,000 Units for an aggregate purchase price of $200,000. The Purchase Price Per Unit shall be allocated $0.135 to each share of COVR Common Stock and $0.49 to each Warrant.
Sample 1
AutoNDA by SimpleDocs
Initial Sales. The Developer agrees to deliver to the Monitoring Agent the income, asset and age certifications, deeds and Affordable Housing Restriction with respect to initial sales of Affordable Units as required under the Regulatory Agreement (the “Initial Sales Data”). The Monitoring Agent agrees to review the Initial Sales Data and determine the substantive compliance of each initial sale of an Affordable Unit with the Affordability Requirement in accordance with the rules of the Subsidizing Agency. Prior to the Developer’s delivery of the deed making the initial conveyance of each Affordable Unit, the Subsidizing Agency will issue a Resale Price Certificate (as defined in the Affordable Housing Restriction) to the Monitoring Agent with the calculated Resale Price Multiplier, which shall be applied to the Affordable Housing Restriction. The Monitoring Agent shall deliver such Resale Price Certificate, together with the Affordable Housing Restriction and the Affordable Housing Restriction Mortgage (both as defined in the Regulatory Agreement), and the Certificate of Compliance (as defined in the Affordable Housing Restriction), to the Developer for the closing on the sale of such Affordable Unit, and shall verify that the Developer, as a condition of sale, ensures that the Resale Price Certificate, the Affordable Housing Restriction, the Affordable Housing Restriction Mortgage, and the Certificate of Compliance are all recorded with the Registry immediately after the initial deed for such Affordable Unit. Upon completion of the initial sales of Affordable Units, the Monitoring Agent shall deliver to the Subsidizing Agency and the Municipality a copy of such data together with the Monitoring Agent’s written determination, in form and substance acceptable to the Subsidizing Agency, of whether the Affordability Requirement has been met and, if not, the action(s) the Monitoring Agent is taking to achieve full compliance with the Affordability Requirement (in which case, the Monitoring Agent shall deliver a supplemental written confirmation of compliance when achieved) (such determination, including any applicable supplemental confirmation, the “Initial Sales Affordability Completion Report”).
Sample 1

Related to Initial Sales

  • Gross Sales Notwithstanding anything in the Lease to the contrary the definition of Gross Sales shall be as follows:

  • Product Sales Subject to Sections 10.3(c) and 10.3(d), Licensee agrees that it will not sell, offer for sale, or assist third parties (including Affiliates) in selling Product except for the sale and offer for sale of (A) TAF Product, TAF Combination Product, TDF Product and TDF Combination Product for use in the Field and in the countries of the TDF-TAF Territory, (B) COBI Product and COBI Combination Product for use in the Field and in the countries of the COBI Territory, and (C) EVG Product, EVG Combination Product and Quad Product for use in the Field and in the countries of the EVG-Quad Territory.‌ (i) Licensee agrees that during the period in which the Patents are valid and enforceable (on a Product-by-Product basis) it will prohibit its Distributors from selling Product (A) to any other wholesaler or distributor, (B) outside the Territory for which Licensee is licensed for sale of such Product pursuant to Section 2.2, or (C) for any purpose outside the Field. (ii) Licensee agrees that it will not administer the TAF Quad to humans, or sell the TAF Quad until Gilead has obtained marketing approval for the TAF Quad from the FDA. Licensee agrees that it will not administer EVG to humans, or sell Products containing EVG until Gilead has obtained marketing approval for an EVG Product from the FDA. Licensee agrees that it will not administer COBI to humans, or sell Products containing COBI until Gilead has obtained marketing approval for a COBI Product from the FDA. Licensee agrees that it will not administer TAF to humans, or sell Products containing TAF until Gilead has obtained marketing approval for a TAF Product from the FDA. If Gilead obtains marketing approval from the FDA for any Quad Product or a Combination Product containing TAF, COBI or EVG (“Approved Combination Product”) prior to obtaining marketing approval for a TAF Product, EVG Product or COBI Product from the FDA, then Licensee will be allowed to administer such Quad Product or such Approved Combination Product to humans, and sell such Quad Product or such Approved Combination Product from and after the date of such marketing approval from the FDA, but will not (A) administer to humans or sell Combination Products containing EVG other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for an EVG Product, or (B) administer to humans or sell Combination Products containing COBI other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for a COBI Product or (C) administer to humans or sell Combination Products containing TAF other than such Quad Product or such Approved Combination Product until Gilead has obtained marketing approval from the FDA for a TAF Product.

  • Net Sales The term “

  • Calendar Year Calendar Year" for the purposes of this Agreement shall mean the twelve (12) month period from January 1st to December 31st, inclusive.

  • Contract Quarterly Sales Reports The Contractor shall submit complete Quarterly Sales Reports to the Department’s Contract Manager within 30 calendar days after the close of each State fiscal quarter (the State’s fiscal quarters close on September 30, December 31, March 31, and June 30). Reports must be submitted in MS Excel using the DMS Quarterly Sales Report Format, which can be accessed at xxxxx://xxx.xxx.xxxxxxxxx.xxx/business_operations/ state_purchasing/vendor_resources/quarterly_sales_report_format. Initiation and submission of the most recent version of the Quarterly Sales Report posted on the DMS website is the responsibility of the Contractor without prompting or notification from the Department’s Contract Manager. If no orders are received during the quarter, the Contractor must email the DMS Contract Manager confirming there was no activity.

  • Sales Milestone Payments Artiva shall make the following one-time, non-refundable and non-creditable sales milestone payments to GCLC when the aggregate annual Net Sales of Products in the Territory first reach the thresholds specified below. Artiva shall notify GCLC promptly of the achievement of each such sales threshold. Each sales milestone payment shall be made by Artiva within [***] days after the end of the calendar quarter in which such sales threshold is achieved. To the extent more than one sales threshold is reached in any given calendar year, then the applicable milestone payment for each such achievement shall be due and owing with respect to such calendar year. For clarification, the total milestone payments payable hereunder if all milestone events are achieved is [***].

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Gross Receipts The entire amount of all receipts, determined on a cash basis, from (a) tenant rentals collected pursuant to tenant leases of apartment units, for each month during the term hereof; provided that there shall be excluded from tenant rentals any tenant security deposits (except as provided below); (b) cleaning, tenant security and damage deposits forfeited by tenants in such period; (c) laundry and vending machines income; (d) any and all other receipts from the operation of the Project received and relating to the period in question; (e) proceeds from rental interruption insurance, but not any other insurance proceeds or proceeds from third-party damage claims, and (f) any other sums and charges collected in connection with termination of the tenant leases. Gross Receipts also does not include the proceeds of (i) any sale, exchange, refinancing, condemnation, or other disposition of all or any part of the Project, (ii) any loans to Owner whether or not secured by all or any part of the Project, (iii) any capital expenditures or funds deposited to cover costs of operations made by Owner, and (iv) any insurance policy (other than rental interruption insurance or proceeds from third-party damage claims).

  • Reporting Period Project progress including a summary of progress, findings, data, analyses, results and field-test results from all tasks carried out in the covered period.

  • Royalty Term On a country-by-country and Licensed Product-by-Licensed Product basis, royalty payments in the Territory shall commence upon the first commercial sale of such Licensed Product, whether such sale is to a Public Purchaser, Governmental Authority or private entity or person and whether such sale is made under an EUA or Key Approval, in such country in the Territory and will terminate upon the later of: (a) the expiration, invalidation or abandonment date of the last Valid Claim of the Patents in the country of sale or manufacture of such Licensed Product in the Territory or (b) expiration of regulatory exclusivity of such Licensed Product in such country of sale in the Territory (the “Royalty Term”).

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!